Maravai LifeSciences Announces November 2023 Investor Conference Schedule
09 Noviembre 2023 - 7:15AM
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of
life science reagents and services to researchers and biotech
innovators, is scheduled to participate in the following investor
conferences during the month of November.
On November 14, 2023, at 10:55 a.m. EST, Trey Martin, Chief
Executive Officer (CEO) and Kevin Herde, Chief Financial Officer
(CFO), will participate in a fireside chat at the Stifel Healthcare
Conference, 2023, being held at the Lotte New York Palace Hotel, in
New York City, NY.
On November 16, 2023, at 2:00 p.m. GMT, Trey Martin, Chief
Executive Officer (CEO) and Kevin Herde, Chief Financial Officer
(CFO), will participate in a fireside chat at the Jefferies London
Healthcare Conference, 2023, being held at the Waldorf Hilton, in
London, England.
A live webcast of the presentations will be available to all
interested parties on the Maravai LifeSciences Investor Relations
website, under News & Events. An archived version of the
webcasts will also be available on the Maravai website following
the completion of each event.
About Maravai
Maravai is a leading life sciences company providing critical
products to enable the development of drug therapies, diagnostics,
and novel vaccines and to support research on human diseases.
Maravai’s companies are leaders in providing products and services
in the fields of nucleic acid synthesis and biologics safety
testing to many of the world’s leading biopharmaceutical, vaccine,
diagnostics, and cell and gene therapies companies.
For more information about Maravai LifeSciences, visit
www.maravai.com.
Contact Information:
Media Contact: Sara Michelmore MacDougall Advisors+1
781-235-3060 maravai@macdougall.bio
Investor Contact: Deb Hart Maravai LifeSciences +1 858-988-5917
ir@maravai.com
Maravai LifeSciences (NASDAQ:MRVI)
Gráfica de Acción Histórica
De Ene 2025 a Feb 2025
Maravai LifeSciences (NASDAQ:MRVI)
Gráfica de Acción Histórica
De Feb 2024 a Feb 2025